Harith Rajagopalan Sells 90,972 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan sold 90,972 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $1.82, for a total value of $165,569.04. Following the transaction, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at $894,218.78. This represents a 15.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Harith Rajagopalan also recently made the following trade(s):

• On Monday, November 11th, Harith Rajagopalan sold 96,517 shares of Fractyl Health stock. The shares were sold at an average price of $2.47, for a total value of $238,396.99.

Fractyl Health Trading Down 7.6 %

GUTS stock opened at $1.70 on Tuesday. The firm has a market cap of $81.77 million and a P/E ratio of -0.14. The business’s 50 day moving average is $2.06 and its 200-day moving average is $2.51. Fractyl Health, Inc. has a 1-year low of $1.68 and a 1-year high of $13.99. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The business had revenue of $0.01 million for the quarter. Equities analysts anticipate that Fractyl Health, Inc. will post -1.66 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley decreased their target price on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a research report on Monday.

Hedge Funds Weigh In On Fractyl Health

A number of large investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in Fractyl Health by 166.5% during the 3rd quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock valued at $1,269,000 after purchasing an additional 313,335 shares during the period. State Street Corp raised its holdings in Fractyl Health by 129.4% during the 3rd quarter. State Street Corp now owns 113,415 shares of the company’s stock worth $287,000 after buying an additional 63,968 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Fractyl Health by 4.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock valued at $2,646,000 after purchasing an additional 49,289 shares during the period. Barclays PLC boosted its position in Fractyl Health by 1,754.7% during the 3rd quarter. Barclays PLC now owns 47,796 shares of the company’s stock worth $121,000 after acquiring an additional 45,219 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in Fractyl Health during the third quarter worth $85,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.